<DOC>
	<DOCNO>NCT02867852</DOCNO>
	<brief_summary>Carcinomas salivary gland ( SGCs ) rare tumor . Some select salivary gland histotypes salivary duct carcinoma ( SDC ) adenocarcinoma , NOS ( otherwise specify ) distinguish expression androgen receptor ( AR ) , report 21 % 43 % case . Thus , similarly prostate cancer ( Pca ) , androgen deprivation therapy ( ADT ) suggest beneficial patient recurrent disseminate AR-expressing disease . No therapy except palliative chemotherapy available progression ADT , thus underling necessity alternative therapeutic approach .</brief_summary>
	<brief_title>Abiraterone Acetate Patients With Relapsed and/or Metastatic Salivary Gland Cancers</brief_title>
	<detailed_description>Carcinomas salivary gland ( SGC ) rare tumor . They comprise less 1 % cancer head neck . The standard treatment surgical excision , follow radiotherapy select case , high-grade tumor , and/or presence perineural invasion , and/or presence advance disease . Some select salivary gland histotypes salivary duct carcinoma ( SDC ) adenocarcinoma , NOS ( otherwise specify ) distinguish expression androgen receptor ( AR ) , report 21 % 43 % case . Thus , similarly prostate cancer ( Pca ) , androgen deprivation therapy ( ADT ) suggest beneficial patient recurrent disseminate AR-expressing disease . The proven activity ADT AR express SGC well Pca , suggest common clinical behaviour apparently share biological background . Once Pca become resistant castration still remain driven ligand-dependent AR signal hormonal manipulation active efficacious . Abiraterone acetate currently approve FDA castration-resistant prostate cancer ( CRPC ) . We treat abiraterone two patient AR-positive adenocarcinoma progress ADT , patient show partial response suggest activity second line hormonal therapy SGCs . Based biological clinical evidence , aim trial ass activity abiraterone AR-expressing castration resistant SGCs .</detailed_description>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Signed informed consent Age ≥18 year Histologically cytologically confirm salivary gland cancer At least , one target lesion define RECIST 1.1 ( clear progression disease require presence one target lesion previously treat radiotherapy Clinical and/or radiological progression disease ADT Ongoing androgen deprivation serum testosterone level le 50 ng per deciliter ( 1.7 nmol per liter ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Adequate bone marrow function : Neutrophils &gt; 1.5 x 109/L ; Hemoglobin ≥ 9.0 g/dL independent transfusion platelet count ≥ 100,000/μL No limit require number previous chemotherapy line Serum albumin ≥ 3.0 g/dL Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) calculate creatinine clearance ≥ 60 mL/min Serum potassium ≥3.5 mmol/L Able swallow study drug whole tablet Patients treat brain metastasis , stable within last three month , allow Subjects partner childbearing potential must use method birth control adequate barrier protection determine acceptable investigator 13 week last study drug administration Received abiraterone acetate within last 5 year Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection Abnormal liver function consist follow : Serum bilirubin ≥ 1.5 x ULN ( except subject document Gilbert 's disease , upper limit serum bilirubin 3 mg/dL ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥ 2.5 x ULN Patients ALT and/or AST exceed 5 x ULN due liver mets enrol Uncontrolled hypertension ( systolic blood pressure ≥160 mmHg diastolic blood pressure ≥95 mmHg ) ; subject history hypertension allow provide blood pressure control antihypertensive therapy Active symptomatic viral hepatitis chronic liver disease History pituitary adrenal dysfunction Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association ( NYHA ) Class III IV heart disease leave ventricular ejection fraction ( LVEF ) &lt; 50 % baseline History gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study drug Any acute toxicity due prior chemotherapy radiotherapy resolve NCICTCAE ( Version 4.0 ) Grade ≤1 Participation clinical trial experimental agent within 30 day study entry concomitant treatment experimental drug Previous concurrent cancer distinct primary site histology cancer evaluate study except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis T1 ) cancer curatively treat &gt; 3 year prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>